BioSpace News Archive

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and Ochsner Health announced a multi-faceted partnership to improve cancer detection rates in Louisiana using Galleri®, GRAIL’s multi-cancer early detection blood test.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the Phase 3 SHINE study (Abstract #7502), which demonstrated that the combination of once-daily oral IMBRUVICA® (ibrutinib) plus bendamustine-rituximab (BR) and rituximab maintenance.

Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced that management will participate at two upcoming conferences in June.

Global alkyl amines market size is expected to reach USD 9,453.2 Million in 2028 and register a revenue CAGR of 5.9% over the forecast period, according to the latest report by Reports and Data.

According to the current analysis of Reports and Data, the global macrogol/polyethylene glycol (PEG) market was valued at USD 5667.81 million in 2021 and is expected to reach USD 10,074.39 million by year 2030, at a CAGR of 6.68%.

Increasing incidence of various types of cancer worldwide, growing demand for radiation therapy for cancer diagnosis and treatments, and rapid advancements in radiation technology are some key factors expected to drive global Medical Radiation Detection, Monitoring, and Safety market growth.

ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases, is pleased to announce sponsorship of an American Diabetes Association Thought Leadership Video on Podocyte Lipotoxicity, a Cause of Diabetic Kidney Disease and Its Progression.

According to Nova one advisor, during the forecast period of 2022 to 2030, the global Brucellosis Vaccine market is estimated to develop at a compound annual growth rate (CAGR) of 4.2%.

Findings from two studies funded by the ADA Pathway to Stop Diabetes research program highlight innovative science and the latest diabetes developments on genomic profiling and glucose control.

According to Nova one advisor, during the forecast period of 2022 to 2030, the global Solitary Fibrous Tumor Treatment market is estimated to develop at a compound annual growth rate (CAGR) of 4.5%.